Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults

ConditionHealthy Aging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-75
Sponsordsm-firmenich Switzerland AG

About this trial

To assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria) Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo

Eligibility criteria

Qualifiers

Participant is male or female, 50-75 years of age, inclusive.

Participant has a Body Mass Index (BMI) of ≥18.5 kg/m2 to 32 kg/m2.

Participant is generally in good health, as per investigator's judgement at V1.

Participant has subjective mild to moderate memory complaints, as per investigator's judgement.

Disqualifiers

Participant has a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disease, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other clinically significant psychiatric/neurologic condition that, in the opinion of the investigator, could interfere with the interpretation of the study results.

MMSE score at V1 < 21.

Chronic fatigue syndrome.

Women: elevated stress and/or anxiety levels clearly related to the (peri) menopause complaints, as per investigator judgement

Trial design

Treatments tested in this trial

  • Humiome Post LB (Postbiotic)
  • Placebo

Treatment groups

236 Participants
are divided into 2 treatment groups

Sponsors and collaborators

dsm-firmenich Switzerland AG

Lead sponsor

Analyze & Realize

Collaborator